Seagen Inc (SGEN)

Add to Watchlists
Create an Alert
Quickflows
151.11 +1.02  +0.68% NASDAQ Feb 26, 20:00 USD
View Full Chart
Price Chart
View All Key Stats

Key Stats

View All SGEN News

News

View All Events

Events

Date Type Description
04/30/2021 Earnings Seattle Genetics Inc First Quarter Earnings Results for 2021
04/30/2021 Misc Seattle Genetics Inc First Quarter Earnings Conference Call for 2021
02/11/2021 Earnings Seagen Inc Fourth Quarter Earnings Result for 2020
02/11/2021 16:30 EST Misc Seagen Inc Fourth Quarter Earnings Conference Call for 2020
10/29/2020 16:30 EDT Misc Seagen Inc Third Quarter Earnings Conference Call for 2020
10/29/2020 Earnings Seagen Inc Third Quarter Earnings Result for 2020
07/30/2020 16:30 EDT Misc Seattle Genetics Inc Second Quarter Earnings Conference Call for 2020
07/30/2020 Earnings Seattle Genetics Inc Second Quarter Earnings Result for 2020
05/15/2020 11:00 PDT Misc Seattle Genetics Inc Annual General Meeting for 2019
04/30/2020 16:30 EDT Misc Seattle Genetics Inc First Quarter Earnings Conference Call for 2020
View All Performance Charts

Total Returns Comparison

Fundamentals

Income Statement View Statement

Revenue (TTM) 2.176B
Total Expenses (TTM) 1.579B
Net Income (TTM) 613.67M

Balance Sheet View Statement

Total Assets (Quarterly) 4.001B
Total Liabilities (Quarterly) 512.81M
Shareholders Equity (Quarterly) 3.488B

Cash Flow Statement View Statement

Cash from Operations (TTM) 856.57M
Cash from Investing (TTM) -1.419B
Cash from Financing (TTM) 846.11M

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.seagen.com
  • Investor Relations URL: http://investor.seattlegenetics.com/phoenix.zhtml?c=124860&p=irol-IRHome
  • HQ State/Province: Washington
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Mid Cap/Growth
  • Next Earnings Release: Apr. 30, 2021
  • Last Earnings Release: Feb. 11, 2021
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Seagen Inc is a biotech firm focused on developing antibody-drug conjugates. The company's lead product, Adcetris, has received approval for advanced front-line, relapsed/refractory and post-consolidation Hodgkin lymphoma, anaplastic large-cell lymphoma, and two other subtypes of cutaneous T-cell lymphoma. Other approved products include Padcev (bladder cancer) and Tukysa (breast cancer). The company has several other oncology programs in pivotal trials. Seagen also licenses its antibody-drug conjugate technology to a number of leading biotechnology and pharmaceutical companies.

Analyst Coverage

Consensus Recommendations
Buy Recommendations Upgrade
Outperform Recommendations Upgrade
Hold Recommendations Upgrade
Underperform Recommendations Upgrade
Sell Recommendations Upgrade
Consensus Recommendation Upgrade
Consensus Rating Upgrade
Target Price
Price 151.11
Price Target Upgrade
Price Target Upside (Daily) Upgrade

Top Fund Holders

Symbol Name Weighting
HQL Tekla Life Sciences Investors 4.64%
HQH Tekla Healthcare Investors 4.13%
BBH VanEck Vectors Biotech ETF 3.53%
POAGX PRIMECAP Odyssey Aggressive Growth 2.83%
BMEZ BlackRock Health Sciences Trust II 2.74%
IBB iShares Nasdaq Biotechnology ETF 2.22%
POGRX PRIMECAP Odyssey Growth 2.14%
BME BlackRock Health Sciences 2.11%
SHISX BlackRock Health Sciences Opps Svc 1.97%
VHCOX Vanguard Capital Opportunity Inv 1.86%
JLGZX JPMorgan Large Cap Growth R2 1.80%
THISX T. Rowe Price Health Sciences I 1.29%

Comparables

Edit
MRK Merck & Co Inc
CLBS Caladrius Biosciences Inc
LIFE aTyr Pharma Inc
ABT Abbott Laboratories
CVM CEL-SCI Corp

Other Resources

Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.

Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.